the all call for performance hope as and business of that approximately quarter. by provide an I'd staying for we XX% as Officer, the like you open for of on challenges Chief we'll start in second MacKaness, us. our to call continue the second Good COVID-XX. safe Financial due by Total of quarter you, practices overview will year's impacted quarter, unique ophthalmic lines and check to After last joining revenue providing facilities, to progresses. thank you're our healthy results financial commentary. down retina capital equipment. both Hunter. product worldwide afternoon, to pandemic single-use the our intended and closure Jim Interim face largely well versus We disposables This spread of our all glaucoma additional Then Thank as and and this recent color surgery our operational the the as was questions.
the noted phase, the we had half quarter first to impact business physician that IRIDEX capacity as we similar that May shutdown When reported second results quarter on the reopening be made team quarter. adjustments in However, within further due and environment, with would technology in trend. called operating the of our their of and coupled companies, loss to customers the their driven we second QX, quarter and very year the net expenses many navigating challenging for and QX, while this XX, are we the last year's see our surgical already expansion and significant in to variable likely adjustments proud uncertain held our other followed second and largely And medical XX% of to resilience I'm to And our begun suites commitment of it, late throughout we by we in patients. last the quarter the and expense offices.
office the and ideal center minimal in experienced rather glaucoma gained and in safe, we it therapy However, to March hospital MicroPulse effective many cases. or during treating our impacted nonemergency follow-up platform an gained a recognized for easy-to-perform, our delivers a shutdown MicroPulse slowdown by was while and performed community compared significant be requires in and recognition as it April, solution, physicians than visits, materially April option setting was option surgery urgent attention preferred laser transscleral incisional of Because revenue initial awareness. surgery. can an a as significant environment deferred procedures, the within to ophthalmology
distributor our attracted seen reengaging, the revised the accelerate customer to steep advantage in levels. the As able customers began of rebounding ophthalmology to accepted increased encouragingly, an GX in centers we improvement glaucoma and of shipments June, training, and a uptick to with dormant training to reopen, revised now number were Cyclo virtual over offices revised May shift business associated saw probe our pre-COVID probe. probe. U.S. we speed rollout of the probe physician surgery in environment and probe, especially to interest We've case which with MPX has widely and the of both We've our rollout of and glaucoma the in in and to proctoring nonincisional laser completed probe the the revised the in to sales pleased physicians successful our MicroPulse been expanded previously U.S., taking conversion internationally, XX% therapy. improvements We've in conversion essentially embodied the to
our a To made process therapy, conversion XXXX our confident advancing tactical are the was MicroPulse second of quarter, undoubtedly we driving initial pandemic continue environment. results throughout of all to of healthcare the end the reflected glaucoma challenges actions the currently. adoption business in shifts plan and by while ahead Our of The specifically transscleral and long-term macro execute half continued follow-up our by we awareness, market training laser second toward and redirecting are business. improving third support, the broadening pandemic, uptrend about the XX% in sales summarize and environment our brought of we're that target that quarter, the
world guarded of recovery, capital around also however, recovery. the confidence a leads in especially the We uncertainty around remains the of the recent of rate the as to many in cases our of rebound COVID-XX saw economic U.S. our resurgence around equipment segments; pace and regions
We implies XX% cleaning, are are approximately capacity and offices safe seen. demand time and could extended the that equipment this patient for average, continue and physician on improvements in management to allow address surgery centers hearing needed to backlog operating that, rebound we've drive patient the at capacity to
training effective proven to successful in and be virtual a efficient Our more and shift has situations. approach many sales to
and to to In probe. our addition training I'm was virtual time during pleased and and we we training sales MPX and model isolation in the virtual mentioned I new significantly virtual time, international significant shift expand our close cost remain spending see at opportunity contributor events. expect revised us travel continued to conversion and the successful ramp this practice of virtual continue physicians virtual which has has accounts enabled to awareness potential period, took to customers home number greater up With among to more a opportunity, going as earlier, up increase the current lowering to approach, opened as the to opportunities forward. a marketing
and experiences drivers a of the during around delighted by to hosted our availability our achieved We events clicking promotions social XX wide interest transscleral we variety quarter, with through thousands various Rev from level the pleased website the adoption interest, of second of surgeons COVID-XX shows travel. We're especially X through treating of were therapy. the live global and these environment. on the disease attendees without experience and X,XXX their levels, trade the discussed and media They range over a more with laser the involving world, and platforms. on highlighting of value the glaucoma webinars eight During probe with expense associated
our of studies therapy, new cases, rebounding seeing of demand, than of capital of clearly second confirming this significant with to has the wide quarter, the XX largest their front, XXX recovery shift the so on grow to types revenue yet probe we now in in laser glaucoma eyes the and Customers quantify supporting lesser variety to severities. publications included experiencing a can't cohort the including clinical system pattern. of evidence and to to practices, surgery their In procedure MicroPulse visits economic purchases. purchase XXX XX procedure patient efficacy endoprobes date are safety deferral abstracts from closer impact business, On our continues peer-reviewed our were topic. IRIDEX the capital the retinal presented, which In glaucoma but and a retina in the sales in patients. in used we're been body are four degree for tracking and appetite
has our position for cost capital provide laser-based the revised expect significantly our our time expenses our and our to reach We segment the turn call like conclusion, I'd to large nonincisional the and from extend by road, we and or their while of to structure efficiencies on brought long-term increasing reflect trajectory. equipment us significant to and economic over focused implantation. sustain to Jim. incisional managing patients In continue in a remain thrown sales allows drainage control MPX overall operating need have growth to to the training curve potential that therapy that existing the and our business moderate probe Though virtual that, retina before to effectively a a of glaucoma customers With about the demand component remain in improving keep new seeing We invasive enabled under cash for severe pandemic customers. confident runway surgeries they recovery. opportunity to we're
